Hide metadata

dc.date.accessioned2023-08-11T17:47:08Z
dc.date.available2023-08-11T17:47:08Z
dc.date.created2023-06-12T09:51:41Z
dc.date.issued2023
dc.identifier.citationRakaee, Mehrdad Andersen, S. Giannikou, K. Paulsen, Erna-Elise Kilvær, Thomas Karsten Rasmussen Busund, Lill-Tove Berg, Thomas Richardsen, Elin Lombardi, Ana Paola Adib, E. Pedersen, Mona Irene Tafavvoghi, Masoud Wahl, Sissel Gyrid Freim Petersen, R.H. Bondgaard, A.L. Yde, C.W. Baudet, C. Licht, P. Lund-Iversen, Marius Grønberg, Bjørn Henning Fjellbirkeland, Lars Helland, Åslaug Pøhl, M. Kwiatkowski, D.J. Dønnem, Tom . Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. Annals of Oncology. 2023
dc.identifier.urihttp://hdl.handle.net/10852/103208
dc.description.abstractBackground We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478 ). Molecular and genomic features associated with immune phenotypes in NSCLC have not been explored in detail. Patients and methods We developed a machine learning (ML)-based model to classify tumors into one of three categories: inflamed, altered, and desert, based on the spatial distribution of CD8+ T cells in two prospective (n = 453; TNM-I trial) and retrospective (n = 481) stage I-IIIA NSCLC surgical cohorts. NanoString assays and targeted gene panel sequencing were used to evaluate the association of gene expression and mutations with immune phenotypes. Results Among the total of 934 patients, 24.4% of tumors were classified as inflamed, 51.3% as altered, and 24.3% as desert. There were significant associations between ML-derived immune phenotypes and adaptive immunity gene expression signatures. We identified a strong association of the nuclear factor-κB pathway and CD8+ T-cell exclusion through a positive enrichment in the desert phenotype. KEAP1 [odds ratio (OR) 0.27, Q = 0.02] and STK11 (OR 0.39, Q = 0.04) were significantly co-mutated in non-inflamed lung adenocarcinoma (LUAD) compared to the inflamed phenotype. In the retrospective cohort, the inflamed phenotype was an independent prognostic factor for prolonged disease-specific survival and time to recurrence (hazard ratio 0.61, P = 0.01 and 0.65, P = 0.02, respectively). Conclusions ML-based immune phenotyping by spatial distribution of T cells in resected NSCLC is able to identify patients at greater risk of disease recurrence after surgical resection. LUADs with concurrent KEAP1 and STK11 mutations are enriched for altered and desert immune phenotypes.
dc.languageEN
dc.publisherKluwer Academic/Plenum Publishers
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleMachine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
dc.title.alternativeENEngelskEnglishMachine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
dc.typeJournal article
dc.creator.authorRakaee, Mehrdad
dc.creator.authorAndersen, S.
dc.creator.authorGiannikou, K.
dc.creator.authorPaulsen, Erna-Elise
dc.creator.authorKilvær, Thomas Karsten
dc.creator.authorRasmussen Busund, Lill-Tove
dc.creator.authorBerg, Thomas
dc.creator.authorRichardsen, Elin
dc.creator.authorLombardi, Ana Paola
dc.creator.authorAdib, E.
dc.creator.authorPedersen, Mona Irene
dc.creator.authorTafavvoghi, Masoud
dc.creator.authorWahl, Sissel Gyrid Freim
dc.creator.authorPetersen, R.H.
dc.creator.authorBondgaard, A.L.
dc.creator.authorYde, C.W.
dc.creator.authorBaudet, C.
dc.creator.authorLicht, P.
dc.creator.authorLund-Iversen, Marius
dc.creator.authorGrønberg, Bjørn Henning
dc.creator.authorFjellbirkeland, Lars
dc.creator.authorHelland, Åslaug
dc.creator.authorPøhl, M.
dc.creator.authorKwiatkowski, D.J.
dc.creator.authorDønnem, Tom
cristin.unitcode185,53,15,12
cristin.unitnameLungeavdelingen
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin2153611
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Annals of Oncology&rft.volume=&rft.spage=&rft.date=2023
dc.identifier.jtitleAnnals of Oncology
dc.identifier.volume34
dc.identifier.issue7
dc.identifier.startpage578
dc.identifier.endpage588
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.1016/j.annonc.2023.04.005
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0923-7534
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International